Blinatumomab Indications Expanded to Include MRD+-B-Cell Precursor ALL

Share this content:
FDA approval was based on the on findings from the phase 2 BLAST study.
FDA approval was based on the on findings from the phase 2 BLAST study.

The US Food and Drug Administration (FDA) has approved an expansion of the indications for blinatumomab (Blincyto®) to include the treatment of pediatric and adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD), according to a news release. 

MRD is the presence of very low but detectable levels of cancer cells during treatment or posttreatment while the patient is in remission. It is one of the most frequent causes of relapse among patients with solid or hematologic malignancies.

Continue Reading Below

The FDA based its approval on findings from the phase 2 BLAST study, for which researchers assigned 86 patients with B-precursor ALL in hematologic complete remission (CR), yet with MRD-positive disease 10-3 or greater, to receive blinatumomab 15 µg/m² daily.

Results showed that approximately 80% of patients achieved a complete MRD response rate after 1 cycle of blinatumomab, and reached the primary end point of the study; the median hematologic relapse-free survival was 22.3 months among study patients. 

The safety profile of blinatumomab remained consistent with those of previous findings; frequently observed adverse events included infections, pyrexia, infusion-related reactions, headache, neutropenia, anemia, febrile neutropenia, and thrombocytopenia. Blinatumomab also carries black box warnings for neurologic toxicities and cytokine release syndrome.


FDA approves Blincyto® (blinatumomab) to treat minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia in adults and children [news release]. Thousand Oaks, CA: Amgen; March 29, 2018. Accessed March 30, 2018.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs